All In Biotech

Drug Trial Radar · NCT05018416

Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

A Phase 2, Randomized, Open-Labeled, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Jul 27, 2021

Primary completion

May 20, 2025

Study completion May 20, 2025

Sponsor

Lead sponsor
ProkidneyIndustry
Sponsor type
Industry
First posted
Aug 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, efficacy, and durability of up to two Renal Autologous Cell Therapy (REACT) / rilparencel injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with Type1 Diabetes Mellitus (T1DM) or Type2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease (CKD).

Conditions

  • Chronic Kidney Diseases
  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus

Interventions

  • Renal Autologous Cell Therapy (REACT)Biological

    Autologous selected renal cells (SRC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equationTime frame: Screening thru month 28
  2. Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.Time frame: Screening thru 18 months after the last injection of study drug

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Kidney Associates of Colorado, P.C. - Frenova

    Denver, Colorado

  • Nephrology Associates

    Newark, Delaware

  • Boise Kidney and Hypertension Institute - Frenova

    Nampa, Idaho

  • Paragon Health, PC d/b/a Nephrology Center, PC - Frenova

    Kalamazoo, Michigan

  • Nephrology and Hypertension Associates Ltd - Frenova

    Tupelo, Mississippi

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.